Karakteristik Pasien Tumor Trofoblas Gestasional Risiko Rendah dengan Kemoresitensi terhadap Metotreksat yang Dirawat di RSUP Dr. Hasan Sadikin Bandung Periode 2011−2015

Ronald Jackson Sinaga, Maringan D. L. Tobing, Ali Budi Harsono

Abstract


Abstrak
Tujuan: Penelitian ini akan mendeskripsikan karakteristik pasien TTG risiko rendah yang resisten terhadap metotreksat di Rumah Sakit Hasan Sadikin Bandung selama periode 2011-2015.
Metode: Penelitian ini merupakan penelitian deskriptif retrospektif, berlokasi di Departemen Obstetri dan Ginekologi dan Instalasi Rekam Medis Rumah Sakit Hasan Sadikin Bandung dari bulan April sampai Mei 2017.
Hasil: Selama periode penelitian didapatkan 46 kasus TTG risiko rendah yang resisten terhadap metotreksat. Jumlah kejadian terbanyak pada rentang usia 31-35 tahun (45,6%), 36,9% dengan paritas 2, 69,6% dengan gejala klinis perdarahan vagina abnormal, 91,3% dengan kehamilan sebelumnya mola hidatidosa, 52,5% kasus memiliki interval antara kehamilan dengan diagnosis TTG ≤ 4 bulan, 60,9% kasus kadar β-hCG awal > 100.000 mIU/ml. Sebanyak 28,3% kasus bermetastasis, 76,9% di paru-paru dan 23% di otak. Sebagian besar kasus TTG ditemukan pada stadium I (65,2%) pada tahap II, III dan IV adalah 10,9%, 15,2% dan 8,7%.
Diskusi: Resistensi terhadap metotreksat pada kasus TTG risiko rendah kebanyakan terjadi pada pasien berusia 31-35 tahun, paritas 2, gejala klinis perdarahan vagina abnormal, kehamilan sebelumnya mola hidatidosa, interval antara kehamilan sebelumnya dengan saat didiagnosis TTG ≤4 bulan, β-hCG awal >100.000 mIU/ml, dan paling banyak ditemukan pada stadium I.

Characteristic of Low Risk Gestational Thropoblastic Neoplasia Patien with Chemoresistance to Methotrexate at Dr.  Hasan Sadikin General Hospital Bandung in 2011−2015

Abstract
Objecttive:  This research will describe the characteristics of patients with low risk GTN with chemoresistancy to methotrexate at Hasan Sadikin Hospital Bandung during the period 2011-2015.
Method: This research was a descriptive retrospective study located at Obstetrics and Gynecology Department and Medical Record Installation of Hasan Sadikin Hospital Bandung from April to May 2017.
Results: During research period that was 46 low risk GTN cases with chemoresistancy to methotrexate. Number of incident mostly in 31−35 years (45,6%), 36,9% with parity 2, 69,6% with clinical symptom of abnormal vaginal bleeding, 91,3% with previous pregnancy hydadityform mole, 52,5% had interval between pregnancy with GTN diagnose was ≤4 months, 60,9% with intial β-hCG >100.000 mIU/ml, 28,3% case metastasized, 76,9% in lung and 23% in brain. Most of the GTN cases found in stage I ( 65,2%), in stage II, III and IV was 10,9%, 15,2% and 8,7%.
Discussion: Chemoresistancy to methotrexate in low risk GTN mostly occur in 31-35 years of age, parity 2, mostly clinical symptom of abnormal vaginal bleeding, hidatydiform mole previous pregnancy, interval between pregnancy was ≤ 4 months, intial β-hCG >100.000 mIU/ml, and mostly found in first stage.

Key words: Low risk gestational thropoblastic neoplasiac, hemoresistant



Keywords


Tumor trofoblas gestasional risiko rendah, kemoresisten

Full Text:

PDF

References


Niemann I, Vejerslev LO, Frøding L, Blaakær J, Maroun LL, Hansen ES, et al. Gestational trophoblastic diseases clinical guidelines for diagnosis, treatment, follow up, and counselling. Danish Med J. 2015;62(11).

Lurain JR. Gestational trophoblastic disease I: epidemiology, pathology, clinical presentation and diagnosis of gestational trophoblastic disease, and management of hydatidiform mole. Am J Obstet Gynecol. 2010;203(6):531-9.

Martaadisoebrata D. Protokol pengelolaan penyakit trofoblas gestasional.Edisi ke 1. Bandung: Pusat Pengelolaan Penyakit Trofoblas Gestasional; 2005.

Lorigan P, Sharma S, Bright N, Coleman R, Hancock B. Characteristics of women with recurrent molar pregnancies. Gynecol Oncol. 2000;78(3):288-92.

Hancock B, Welch E, Gillespie A, Newlands E. A retrospective comparison of current and proposed staging and scoring systems for persistent gestational trophoblastic disease. Int J Gynecol Cancer. 2000;10(4):318-22.

Lybol C, Sweep FC, Ottevanger PB, Massuger LF, Thomas CM. Linear regression of postevacuation serum human chorionic gonadotropin concentrations predicts postmolar gestational trophoblastic neoplasia. Int J Gynecol Cancer. 2013;23(6):1150-6.

Lobo RA, Gershenson DM, Lentz GM, Valea FA. Comprehensive gynecology.Edisi ke 7. Oxford: Elsevier; 2017.

Hemida RAE, Toson E, Shalaby H, Refaie E, Eldin DS. Chemo-resistant gestational trophoblastic neoplasia, 5-years experience of mansoura university hospital, egypt. OJOG. 2011;1:153-7.

Taylor F GT, Everard J, Ellis L, Winter MC, Tidy J, Hancock BW, Coleman RE. The outcome of patients with low risk gestational trophoblastic neoplasia treated with single agent intramuscular methotrexate and oral folinic acid. European J Cancer. 2013;49(15):3184-90.

Ngu S-F, Chan KK. Management of chemoresistant and quiescent gestational trophoblastic disease. Current Obstet Gynecol. 2014;3(1):84-90.

Neubauer NL, Strohl AE, Schink JC, Lurain JR. Fatal gestational trophoblastic neoplasia: An analysis of treatment failures at the Brewer Trophoblastic Disease Center from 1979–2012 compared to 1962–1978. Gynecol oncol. 2015;138(2):339-42.

Strohl A, Lurain J. Postmolar choriocarcinoma: An independent risk factor for chemotherapy resistance in low-risk gestational trophoblastic neoplasia. Gynecol Oncol. 2016:1-5.

Gueye M, Gueye M, Gueye S, Dia F, Thiam A, Diouf S, et al. Efficacy and Risk Factors Associated to Resistance to Single-Agent Chemotherapy in Low-Risk Gestational Trophoblastic Neoplasia. Open J Obs Gynecol. 2016;6:50-5.

Winter M, Tidy J, Hills A, Ireson J, Gillett S, Singh K, et al. Risk adapted single-agent dactinomycin or carboplatin for second-line treatment of methotrexate resistant low-risk gestational trophoblastic neoplasia. Gynecol Oncol. 2016:1-6.

You B, Harvey R, Mitchell H, Golfier F, Savage P, Tod M, et al. Early prediction of treatment resistance in low-risk gestational trophoblastic neoplasia using population kinetic modelling of hCG measurements. Brit J of Can. 2013;108:1810-6.

Feng F, Xiang Y, Wan X, Zhou Y. Prognosis of patients with relapsed and chemoresistant gestational trophoblastic neoplasia transferred to the Peking Union Medical College Hospital. BJOG. 2010;117:47–52.

Gillani M, Fariba B, Behtash N, Gaemmaghami F, Moosavi A, Rezayof E. The WHO score predicts treatment outcome in low risk gestational trophoblastic neoplasia patients treated with weekly intramuscular methotrexate. J Can Res Ther. 2013;9(1):38-43.

Byun S, Park T, Bae S. Conservative Chemotherapy in Gestational Trophoblastic Disease Experience With Etoposide, Methotrexate, and Dactinomycin Chemotherapy. Int J Gynecol Cancer. 2016;26(4):790-5.

Mousavi AS, Zamani A, Khorasanizadeh F, Gilani MM, Zendehdel K. Resistance to single‐agent chemotherapy and its risk factors in low‐risk gestational trophoblastic neoplasms. J Obstet Gynecol Res. 2015;41(5):776-83.

Lybol C, Sweep FC, Harvey R, Mitchell H, Short D, Thomas CM, et al. Relapse rates after two versus three consolidation courses of methotrexate in the treatment of low-risk gestational trophoblastic neoplasia. Gynecol Oncol. 2012;125(3):576–9.

Laul P SP, Kadam VK, Miglani U. Two interesting cases of gestational trophoblastic disease with methotrexate failure. Int J Reprod Contracept Obstet Gynecol.; 2016. p. 3251-3.




DOI: http://dx.doi.org/10.24198/obgynia.v1n2.47

Refbacks

  • There are currently no refbacks.


Alamat Redaksi

 

KSM/Dep Obstetri & Ginekologi Fakultas Kedokteran Universitas Padjadjaran RSUP Dr. Hasan Sadikin

Jl. Pasteur No 38 Bandung 40161 

Telp: 0813-2012-9954

Email: obgyniajurnal@gmail.com

 

 

 




Indexed By
         



Web Analytics
View My Stats

Indonesian Journal of Obstetrics & Gynecology Science @2017